CYTOSORBENTS APPOINTS DR. EFTHYMIOS N. DELIARGYRIS, M.D.

CYTOSORBENTS APPOINTS DR. EFTHYMIOS N. DELIARGYRIS, M.D.,

AS CHIEF MEDICAL OFFICER

MONMOUTH JUNCTION, N.J., April 27, 2020

- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification

technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the appointment

of Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI as Chief Medical Officer, to begin employment on May 1, 2020.

Dr. Deliargyris brings over 19 years of

experience in both academic medicine and industry to the position of Chief Medical Officer. From 2010-2016, Dr. Deliargyris held

roles of increasing responsibility as Vice President, European Medical Director, based in Munich, Germany and Global Medical Lead

- Acute Cardiovascular Care at The Medicines Company, acquired by Novartis AG this year. Most recently Dr. Deliargyris was Chief

Medical Officer of PLx Pharma, a NASDAQ-traded, U.S. specialty pharmaceutical company.

Dr. Deliargyris' clinical expertise

spans all aspects of critical care medicine and cardiovascular disease. In addition, his original research, including large, seminal

clinical trials in thrombosis and anti-thrombotic drugs is internationally recognized with more than 100 publications in top journals

and multiple awards, including the prestigious Society of Cardiac Angiography & Interventions (SCAI) Fellowship Award for best

research in interventional cardiology. Dr. Deliargyris' efforts contributed to bivalirudin's blockbuster status in

interventional cardiology and to the approval of cangrelor, a P2Y12 receptor antagonist in the same anti-platelet class

as ticagrelor, in both the U.S. and Europe. Dr. Deliargyris is an elected Fellow of the American College of Cardiology (FACC),

European Society of Cardiology (FESC) and Society for Cardiac Angiography and Interventions (FSCAI).

Dr. Deliargyris commented, "I am

very excited about joining this talented executive team during a time of tremendous progress as evidenced by FDA Emergency

Use Authorization of CytoSorb for critically-ill COVID-19 patients, and also FDA Breakthrough Designation for removal

of ticagrelor during on-pump emergent and urgent cardiothoracic surgery. Whether silencing the cytokine storm or eliminating the

risk of life-threating bleeding, CytoSorb is a game-changer with the potential to save thousands of lives and millions of healthcare

dollars. We plan to design and execute a world-class clinical trial program and generate the necessary data to support regulatory

approvals and establish CytoSorb as a life-saving therapy in multiple indications in the intensive care unit and cardiac surgery."

Dr. Phillip Chan, MD, PhD, Chief Executive

Officer of CytoSorbents stated, "We are thrilled to have Efthymios ("Makis") join CytoSorbents to lead worldwide

clinical activity in critical care and cardiac surgery applications during this exciting chapter at our company. His extensive

expertise in cardiology, interventional cardiology, and the treatment of complications of critical illnesses such as shock, through

many years of clinical practice, clinical trial research, and industry focus, make him well-suited for this task."

Dr. Chan continued, "A new exciting

growth opportunity for the company is the recent European Union approval of CytoSorb to remove the widely-used blood thinner,

ticagrelor, during emergent or urgent cardiothoracic surgery. Left unopposed, ticagrelor can cause serious, life-threatening perioperative

bleeding complications. Our goal is to make CytoSorb a standard of care therapy for this application. Makis is a subject matter

expert in the clinical development, usage, and complications of anti-coagulants and anti-thrombotics such as ticagrelor, cangrelor,

bivalirudin, and aspirin. Throughout his international career, Makis has forged strong relationships with collaborators and key

opinion leaders around the world in this therapeutic area that have been crucial in changing clinical practice. Because of this,

we believe Makis can help to accelerate the awareness and usage of CytoSorb for this purpose throughout the world, and is the

ideal person to leverage the FDA Breakthrough Designation announced last week, and collaborate with the FDA to support

U.S. approval of CytoSorb for this application as well."

Dr. Deliargyris received his Medical Degree

from the Kapodistrian University School of Medicine in Athens, Greece and completed his residency in internal medicine at Tufts

University School of Medicine in Boston where he also served as Chief Resident. He completed his fellowship in cardiology and interventional

cardiology at the University of North Carolina at Chapel Hill where he also served as Chief Fellow. Prior to joining industry,

Dr. Deliargyris served as Director of Cardiology and Interventional Cardiology at Athens Medical Center in Greece and previously

as Assistant Professor of Cardiology and Director of the Intravascular Ultrasound Lab at Wake Forest University Baptist Medical

Center in Winston-Salem, NC.

About CytoSorbents Corporation (NASDAQ:

CytoSorbents Corporation is

a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved

in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce

the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ

failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective

treatments exist. CytoSorb has been used in more than 80,000 human treatments to date. CytoSorb has received FDA Emergency

Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory

failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor

in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents' purification technologies

are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily

fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding

of nearly $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of

Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army,

U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company

has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and

international patents and multiple applications pending, including CytoSorb-XL , HemoDefend , VetResQ , K+ontrol ,

ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and

Forward-Looking Statements

This press release includes forward-looking

statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of

1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations

and contentions and are not historical facts and typically are identified by use of terms such as "may," "should,"

"could," "expect," "plan," "anticipate," "believe," "estimate," "predict,"

"potential," "continue" and similar words, although some forward-looking statements are expressed differently.

You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations,

but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which

could cause or contribute to such differences include, but are not limited to, our ability to leverage designation of CytoSorb

as a breakthrough device under the FDA's Breakthrough Devices Program in order to expedite the development, assessment, and

regulatory review of CytoSorb, as well as the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March

5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press

releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of

the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements,

particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal

regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise

any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under

the Federal securities laws.

CytoSorbents Contact:

Investor Relations Contact:

Public Relations Contact:

Rubenstein Public Relations

SOURCE CytoSorbents Corporation